PL381358A1 - Sposoby i związki pośrednie - Google Patents

Sposoby i związki pośrednie

Info

Publication number
PL381358A1
PL381358A1 PL381358A PL38135805A PL381358A1 PL 381358 A1 PL381358 A1 PL 381358A1 PL 381358 A PL381358 A PL 381358A PL 38135805 A PL38135805 A PL 38135805A PL 381358 A1 PL381358 A1 PL 381358A1
Authority
PL
Poland
Prior art keywords
indirec
compounds
methods
indirec compounds
Prior art date
Application number
PL381358A
Other languages
English (en)
Polish (pl)
Inventor
Gerald J. Tanoury
Minzhang Chen
Andrew D. Jones
Philip L. Nyce
Martin Trudeau
David J. Guerin
John R. Snoonian
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of PL381358A1 publication Critical patent/PL381358A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/04—Formation or introduction of functional groups containing nitrogen of amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
PL381358A 2004-03-12 2005-03-11 Sposoby i związki pośrednie PL381358A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55248004P 2004-03-12 2004-03-12

Publications (1)

Publication Number Publication Date
PL381358A1 true PL381358A1 (pl) 2007-05-28

Family

ID=34962478

Family Applications (4)

Application Number Title Priority Date Filing Date
PL381358A PL381358A1 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie
PL05728092T PL1725548T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL11178126T PL2399915T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL11178128T PL2399916T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL05728092T PL1725548T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL11178126T PL2399915T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy
PL11178128T PL2399916T3 (pl) 2004-03-12 2005-03-11 Sposoby i związki pośrednie do wytwarzania acetali asparaginowych jako inhibitorów kaspazy

Country Status (21)

Country Link
US (4) US7381827B2 (https=)
EP (3) EP2399916B1 (https=)
JP (2) JP4898658B2 (https=)
KR (2) KR101135765B1 (https=)
CN (3) CN1950364B (https=)
AR (1) AR048008A1 (https=)
AU (1) AU2005223767B2 (https=)
BR (1) BRPI0508609B8 (https=)
CA (3) CA2843066C (https=)
DK (3) DK1725548T3 (https=)
ES (3) ES2532967T3 (https=)
HU (1) HUE024556T2 (https=)
IL (3) IL178003A (https=)
PL (4) PL381358A1 (https=)
PT (3) PT2399915E (https=)
RU (2) RU2433127C2 (https=)
SG (2) SG150547A1 (https=)
SI (3) SI1725548T1 (https=)
TW (3) TW201200508A (https=)
WO (1) WO2005090334A2 (https=)
ZA (1) ZA200607605B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
EP1718639A2 (en) * 2004-02-27 2006-11-08 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
MXPA06013256A (es) * 2004-05-15 2007-02-08 Vertex Pharma Tratamiento de crisis convulsivas utilizando inhibidores ice.
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
CA2669917A1 (en) * 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
HRP20120330T1 (hr) * 2007-02-27 2012-05-31 Vertex Pharmaceuticals Incorporated Sukristali i farmaceutski pripravci koji ih sadrže
WO2008106058A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
NZ583699A (en) 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
WO2010017408A1 (en) 2008-08-06 2010-02-11 The Buck Institute For Age Research Caspase inhibitors and uses thereof
US9113848B2 (en) * 2010-02-03 2015-08-25 Covidien Lp Surgical retrieval apparatus
JP5769655B2 (ja) * 2012-03-30 2015-08-26 ユニ・チャーム株式会社 吸収性物品
CN103193572B (zh) * 2013-04-07 2015-06-17 山东大学 一种拉唑类化合物单一对映体的分离方法
ES2950100T3 (es) 2016-12-23 2023-10-05 Casp Aid Inc Inhibición de la caspasa-1 y usos de esta para la prevención y el tratamiento de afecciones neurológicas

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
BE1008343A3 (nl) 1994-05-06 1996-04-02 Dsm Nv Bidentaat fosfineligand
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
AU704318B2 (en) * 1995-11-09 1999-04-22 Pq Nederland B.V. Compacted sodium silicate
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
KR20000036056A (ko) 1996-09-12 2000-06-26 아이디유엔 파마슈티칼즈, 인코포레이티드 인터루킨-1β 전환 효소 및 관련 프로테아제의 억제제로서의 Ｃ-말단 변형된 (Ｎ-치환된)-2-인돌릴 디펩티드
EP0929311B8 (en) 1996-09-12 2006-02-01 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
NZ330451A (https=) 1996-09-12 2000-01-28 Idun Pharmaceuticals Inc
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
WO1998016502A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
NZ334906A (en) 1996-10-11 2000-09-29 Basf Ag A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
FR2766188B1 (fr) 1997-07-15 2000-02-11 Hoechst Marion Roussel Inc Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
ATE388139T1 (de) 1997-12-18 2008-03-15 Boehringer Ingelheim Pharma Pyridone als hemmer der sh2-domäne der src- familie
JP2002509153A (ja) 1998-01-20 2002-03-26 ワーナー−ランバート・カンパニー インターロイキン−１β変換酵素（ＩＣＥ）のインビボ阻害剤としてのＮ−［２−（５−ベンジルオキシカルボニル−アミノ−６−オキソ−２−（４−フルオロフェニル）−１，６−ジヒドロ−１−ピリミジニル）アセトキシル］−Ｌ−アスパラギン酸アルデヒド
DK1064298T3 (da) * 1998-03-19 2009-01-19 Vertex Pharma Inhibitorer af caspaser
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
CA2367862A1 (en) 1999-03-16 2000-09-21 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
JP2002539183A (ja) 1999-03-16 2002-11-19 サイトビア インコーポレイテッド 置換２−アミノベンズアミドカスパーゼインヒビターおよびその使用
CN1176941C (zh) 1999-04-09 2004-11-24 西托维亚公司 Caspase抑制剂及其应用
ES2274795T3 (es) 1999-07-19 2007-06-01 Merck Frosst Canada Ltd. Pirazinonas, composiciones que contienen tales compuestos.
EP1163208B1 (en) 1999-08-06 2004-05-12 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CN1235875C (zh) 1999-08-27 2006-01-11 西托维亚公司 取代的α－羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
PE20011267A1 (es) 2000-03-29 2001-12-15 Vertex Pharma Carbamato como inhibidores de caspasa
AU2001251165A1 (en) 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
CA2402128A1 (en) * 2000-04-24 2001-11-01 Vertex Pharmaceuticals Incorporated Process and intermediates for making substituted aspartic acid acetals
TWI291462B (en) 2000-04-25 2007-12-21 Daiichi Sankyo Co Ltd Hydrate crystal of neuraminic acid compound
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
TR200200767T1 (tr) 2000-05-23 2002-09-23 Vertex Pharmaceuticals Incorporated Kaspaz engelleyiciler ve kullanımları
EP1289993B9 (en) 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CN1498224A (zh) 2000-07-21 2004-05-19 ���鹫˾ 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
WO2002022611A2 (en) 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
AU2002232541A1 (en) 2000-11-21 2002-06-03 Vertex Pharmaceuticals Incorporated Imidazole and benzimidazole caspase inhibitors and uses thereof
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
US20030096737A1 (en) 2001-04-19 2003-05-22 Anita Diu-Hercend Caspase inhibitors and uses thereof
JP4428926B2 (ja) 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
IL159087A0 (en) 2001-07-11 2004-05-12 Vertex Pharma Bridged bicyclic compounds and pharmaceutical compositions containing the same
AU2002348533A1 (en) 2001-10-09 2003-05-26 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
US7960398B2 (en) 2002-04-19 2011-06-14 Vertex Pharmaceuticals Incorporated Regulation of TNF-alpha
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
PE20040728A1 (es) 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
TW200500343A (en) 2002-12-20 2005-01-01 Vertex Pharma Caspase inhibitors and uses thereof
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
EP1718639A2 (en) * 2004-02-27 2006-11-08 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof

Also Published As

Publication number Publication date
SG150547A1 (en) 2009-03-30
JP2012072151A (ja) 2012-04-12
WO2005090334A2 (en) 2005-09-29
CN103467459A (zh) 2013-12-25
PT1725548E (pt) 2015-04-16
US7834200B2 (en) 2010-11-16
CA2559303C (en) 2013-09-10
SG150546A1 (en) 2009-03-30
EP2399915B1 (en) 2014-12-17
DK2399915T3 (en) 2015-03-09
KR20110137409A (ko) 2011-12-22
CN1950364B (zh) 2011-06-08
US20060020016A1 (en) 2006-01-26
US7381827B2 (en) 2008-06-03
RU2433127C2 (ru) 2011-11-10
PL2399916T3 (pl) 2015-06-30
DK2399916T3 (en) 2015-03-02
AU2005223767A1 (en) 2005-09-29
CA2843066A1 (en) 2005-09-29
WO2005090334A3 (en) 2005-11-17
US8293929B2 (en) 2012-10-23
HUE024556T2 (hu) 2016-02-29
CN1950364A (zh) 2007-04-18
CA2768700C (en) 2014-04-29
TWI399356B (zh) 2013-06-21
EP1725548A2 (en) 2006-11-29
EP2399916A1 (en) 2011-12-28
TW201247594A (en) 2012-12-01
HK1163672A1 (en) 2012-09-14
BRPI0508609B8 (pt) 2021-05-25
TW200602341A (en) 2006-01-16
US20130066083A1 (en) 2013-03-14
JP2007528904A (ja) 2007-10-18
IL218487A (en) 2015-08-31
HK1105955A1 (en) 2008-02-29
PL2399915T3 (pl) 2015-07-31
ES2532433T3 (es) 2015-03-26
DK1725548T3 (en) 2015-03-23
ZA200607605B (en) 2009-04-29
PT2399916E (pt) 2015-03-17
SI2399916T1 (sl) 2015-05-29
EP1725548B1 (en) 2015-01-14
PT2399915E (pt) 2015-03-30
IL218488A0 (en) 2012-04-30
CA2843066C (en) 2016-06-07
CN102225936B (zh) 2013-09-11
CA2559303A1 (en) 2005-09-29
AU2005223767B2 (en) 2011-12-01
JP4898658B2 (ja) 2012-03-21
EP2399916B1 (en) 2014-12-10
SI2399915T1 (sl) 2015-05-29
IL178003A (en) 2012-04-30
IL178003A0 (en) 2006-12-31
TWI398426B (zh) 2013-06-11
CA2768700A1 (en) 2005-09-29
US20110071298A1 (en) 2011-03-24
RU2006136032A (ru) 2008-04-20
EP2399915A1 (en) 2011-12-28
BRPI0508609B1 (pt) 2021-03-30
KR101135765B1 (ko) 2012-04-23
RU2011127174A (ru) 2013-01-10
CN102225936A (zh) 2011-10-26
ES2533991T3 (es) 2015-04-16
TW201200508A (en) 2012-01-01
US20090048429A1 (en) 2009-02-19
AR048008A1 (es) 2006-03-15
BRPI0508609A (pt) 2007-07-31
IL218487A0 (en) 2012-04-30
SI1725548T1 (sl) 2015-05-29
PL1725548T3 (pl) 2015-08-31
KR20070006835A (ko) 2007-01-11
ES2532967T3 (es) 2015-04-06

Similar Documents

Publication Publication Date Title
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
AP2006003810A0 (en) 4-Phenylamino-quinazolin-6-yl-amides
PL381358A1 (pl) Sposoby i związki pośrednie
DE502005007040D1 (en) Laryngoskop
EP1737565A4 (en) COS CLAUS CONFIGURATIONS AND METHODS
IL179497A0 (en) Carboranylporphyrins and uses thereof
DE502004004685D1 (en) Giessmaschine
SG119251A1 (en) Methods
GB0424552D0 (en) Methods and means
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0403629D0 (en) Methods
GB0403847D0 (en) Methods and means
DE502004004917D1 (en) Multiaxialkomplex
GB0423552D0 (en) Methods
GB0421911D0 (en) Methods and means
DE502005006813D1 (en) Common-rail-injektor
GB0408156D0 (en) Process and compounds
DE502005004945D1 (en) Auto-splice-system
GB0415757D0 (en) Methods
IL165458A0 (en) And
GB0419181D0 (en) Methods and means
GB0425081D0 (en) Methods and means
GB0421466D0 (en) Methods and means
GB0423658D0 (en) Methods and means
GB0427483D0 (en) Methods and means

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)